Scopolamine N-demethylase capable of catalyzing demethylation reaction of scopolamine to generate N-demethylscopolamine and application thereof

By cloning and expressing the N-northase gene of hipolamine, catalyzing the demethylation reaction of hipolamine to produce N-northosamine, the problems of limited supply and low production efficiency of hipolamine are solved, and the production of ipolamine is improved Efficiency and cost reduction.

CN115851639BActive Publication Date: 2024-11-08SOUTHWEST UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211727074.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-30
Publication Date
2024-11-08
Estimated Expiration
2042-12-30

AI Technical Summary

Technical Problem

The existing production cost of ipratropium bromide is high, mainly due to the limited supply of ipratropium bromide and the low chemical conversion efficiency, which leads to the high-priced price of ipratropium bromide, and the low content of ipratropium bromide in plants, making it difficult to produce on a large scale.

Method used

By cloning and expressing the N-nothase gene of hyosophylamine, catalyzing the demethylation reaction of hyosophylamine to produce N-norexolamine, increasing the content of N-norexolamine in Solanaceae plants, providing a catalyst for isopropyltropus Efficient production of ammonium bromide.

Benefits of technology

The content of N-northocyanine in Solanaceae plants is significantly improved, providing more efficient raw materials for the preparation of ipratropium bromide, and reducing production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115851639B_ABST
    Figure CN115851639B_ABST
Patent Text Reader

Abstract

The invention discloses a hyoscine N-demethylase capable of catalyzing a demethylation reaction of hyoscine to generate N-demethylhyoscine and an application thereof. The amino acid sequence of the hyoscine N-demethylase is shown in SEQ ID NO.4; the nucleic acid sequence encoding the hyoscine N-demethylase is shown in SEQ ID NO.3; research has shown that the enzyme has the function of catalyzing a demethylation reaction of hyoscine to generate N-demethylhyoscine and can increase the content of N-demethylhyoscine in transgenic plants, so the enzyme can be used for increasing N-demethylhyoscine in solanaceous plants through metabolic engineering, and can also be used as a catalyst for catalyzing a demethylation reaction of hyoscine to generate N-demethylhyoscine in chemical synthesis, thereby providing a more efficient raw material for the preparation of ipratropium bromide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of genetic engineering, in particular to a scopolamine N-demethylase capable of catalyzing a demethylation reaction of scopolamine to generate N-demethylscopolamine, and also to the application of the scopolamine N-demethylase. Background Art

[0002] Chronic obstructive pulmonary disease (COPD) is one of the diseases with the highest morbidity and mortality in the world and is incurable. Only drugs can be used to relieve symptoms. Ipratropium bromide is a specific drug for the treatment of COPD. It has the characteristics of rapid action and is often used in the acute exacerbation of COPD. The large number of COPD patients and the reality of long-term medication have led to a huge market demand for ipratropium bromide and high prices, and the economic burden of medication for patients is heavy. At present, ipratropium bromide is often produced by chemical semi-synthesis. The production route of ipratropium bromide is as follows: using scopolamine as the starting material, it is chemically N-demethylated to generate norhyoscyamine; norhyoscyamine is substituted with 2-bromopropane and methyl bromide in sequence to finally generate ipratropium bromide.

[0003] Scopolamine is not only an essential raw material for the production of ipratropium bromide, but also one of the commonly used anticholinergic drugs in clinical practice. The industrial production of scopolamine is completely dependent on extraction from a few Solanaceae medicinal plants, including Atropa belladonna, Datura species, and Anisodus acutangulus. The content of scopolamine in medicinal plants is very low. For example, the scopolamine content of Atropa belladonna, which has the largest scale of planting, is about 0.2% of the dry weight of the leaves, resulting in limited supply of scopolamine and high market prices. The limited production status of scopolamine is one of the main reasons for the high price of ipratropium bromide; in the process of converting scopolamine to norscopolamine by chemical means, the yield is not high and there are many by-products, which further leads to high production costs of ipratropium bromide.

[0004] The key to reducing the production cost of propionium bromide is to simultaneously improve the production efficiency of scopolamine and norhyoscyamine. Therefore, researchers explored the use of plant metabolic engineering technology to achieve a method of efficiently converting scopolamine into norhyoscyamine in plants. For example, overexpressing key enzyme genes in the secondary metabolic biosynthetic pathway in plants can break the rate-limiting step of metabolite synthesis, thereby promoting the accumulation of final useful metabolites in the plant body and obtaining more economically valuable materials. The application of plant metabolic engineering depends on the analysis of the biosynthetic pathway of secondary metabolites. Therefore, cloning the norhyoscyamine biosynthetic gene in drug-derived plants is of great significance for the efficient production of norhyoscyamine in plants. Summary of the invention

[0005] In view of this, one of the objects of the present invention is to provide a scopolamine N-demethylase that catalyzes the demethylation reaction of scopolamine to generate N-demethylscopolamine; a second object of the present invention is to provide a scopolamine N-demethylase gene that catalyzes the demethylation reaction of scopolamine to generate N-demethylscopolamine; a third object of the present invention is to provide a recombinant vector containing a nucleic acid sequence encoding the scopolamine N-demethylase; a fourth object of the present invention is to provide a transformant containing a nucleic acid sequence encoding the scopolamine N-demethylase The fifth object of the present invention is to provide the use of the scopolamine N-demethylase or the scopolamine N-demethylase gene in increasing the N-demethylscopolamine content in Solanaceae plants; the sixth object of the present invention is to provide the use of a recombinant vector containing the scopolamine N-demethylase gene in increasing the N-demethylscopolamine content in Solanaceae plants; the seventh object of the present invention is to provide the use of the scopolamine N-demethylase as a catalyst for catalyzing the demethylation reaction of scopolamine to generate N-demethylscopolamine.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] 1. A scopolamine N-demethylase capable of catalyzing the demethylation reaction of scopolamine to generate N-demethylscopolamine, wherein the amino acid sequence of the scopolamine N-demethylase is shown in SEQ ID NO.4.

[0008] 2. A scopolamine N-demethylase gene that catalyzes the demethylation reaction of scopolamine to generate N-demethylscopolamine, wherein the nucleic acid sequence of the scopolamine N-demethylase gene is shown in SEQ ID NO.3.

[0009] 3. A recombinant vector containing a nucleic acid sequence encoding the scopolamine N-demethylase.

[0010] 4. A transformant containing the nucleic acid sequence encoding the scopolamine N-demethylase.

[0011] 5. Use of the scopolamine N-demethylase or the scopolamine N-demethylase gene in increasing the N-demethylscopolamine content in Solanaceae plants.

[0012] Preferably, the Solanaceae plant is Belladonna, Datura or Tripterygium wilfordii.

[0013] 6. Use of a recombinant vector containing the scopolamine N-demethylase gene for increasing the N-demethylscopolamine content in Solanaceae plants.

[0014] Preferably, the recombinant vector is obtained by replacing the GUS gene on pBI121 with the nucleic acid sequence encoding the scopolamine N-demethylase.

[0015] 7. Use of the scopolamine N-demethylase as a catalyst for catalyzing the demethylation reaction of scopolamine to generate N-demethylscopolamine.

[0016] Preferably, the catalysis occurs in a host cell or is chemically synthesized in vitro.

[0017] The invention has the beneficial effects that: the invention discloses a hyoscine N-demethylase hyoscine N-demethylase capable of catalyzing a demethylation reaction of hyoscine to generate N-demethylhyoscine, the amino acid sequence of which is shown in SEQ ID NO.4; the nucleic acid sequence encoding the hyoscine N-demethylase is shown in SEQ ID NO.3; research has found that the enzyme has the function of catalyzing a demethylation reaction of hyoscine to generate N-demethylhyoscine, and can increase the content of N-demethylhyoscine in transgenic plants, so the enzyme can be used for increasing N-demethylhyoscine in Solanaceae plants through metabolic engineering, and can also be used as a catalyst for catalyzing a demethylation reaction of hyoscine to generate N-demethylhyoscine in chemical synthesis, thereby providing a more efficient raw material for the preparation of ipratropium bromide. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:

[0019] Figure 1 This is the mass spectrometry test result of scopolamine;

[0020] Figure 2 This is the mass spectrometry test result of scopolamine;

[0021] Figure 3 The results of the detection of transgenic belladonna hairy roots by fluorescent quantitative PCR (Control is the control, OE1, OE2, and OE3 are different transgenic lines);

[0022] Figure 4This is the detection result of scopolamine content (Control is the control, OE1, OE2, and OE3 are different transgenic strains). DETAILED DESCRIPTION

[0023] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0024] Example 1. Cloning of the hyoscyamine N-demethylase (HNDM) gene

[0025] (1) Extraction of total RNA from Solanum melongena root fibers

[0026] Take an appropriate amount of Atropa belladonna root tissue, grind it in liquid nitrogen, add it to a 1.5 mL Eppendorf (EP) centrifuge tube containing lysis solution, shake it thoroughly, and extract total RNA according to the instructions of the TIANGEN kit. Use formaldehyde denaturing gel electrophoresis to identify the quality of total RNA, and measure the RNA concentration on a spectrophotometer.

[0027] (2) Cloning of HNDM gene

[0028] The extracted total RNA was used as a template to synthesize cDNA according to the instructions of Tiangen FastKing cDNA First-Strand Synthesis Kit; HAR gene-specific primers were designed, and the specific primers are as follows:

[0029] HNDM-F: 5'-atggattttcatattctttcccat-3' (SEQ ID NO. 1);

[0030] HNDM-R: 5'-ttaaacctcataatacacaggaatca-3' (SEQ ID NO. 2).

[0031] The HNDM gene was amplified from the total cDNA by PCR and sequenced, and the nucleotide sequence of the HNDM gene was obtained as a result of sequencing, and the specific sequence is shown in SEQ ID NO. 3. The start codon is ATG, and the stop codon is TAA; the translated protein coding sequence is shown in SEQ ID NO. 4.

[0032] Example 2: Verification of the function of the HNDM gene by heterologous expression in yeast

[0033] (1) Heterologous expression of HNDM protein in yeast cells

[0034] The HNDM gene was amplified by PCR, and the restriction site BamHI was introduced in the forward primer, and the restriction site XbaI was introduced in the reverse primer. The two restriction sites were used to connect the complete sequence of the HNDM coding region to the yeast expression plasmid pYES2 to obtain the HNDM heterologous expression vector pYES2-HNDM. The primers are as follows:

[0035] BamHI-HNDM-F: 5'-ctcggatccatggattttcatattctttcccat-3' (SEQ ID NO. 5);

[0036] XbaI-HNDM-R: 5'-gtgtctagattaaacctcataatacacaggaatca-3' (SEQ ID NO. 6).

[0037] The constructed pYES2-HNDM plasmid was transformed into the yeast expression strain WAT11, and the positive clones were screened by PCR to obtain the heterologous expression engineered bacteria WAT11-pYES2-HNDM. Take 100μL of WAT11-pYES2-HNDM bacterial solution and inoculate it into 10mL SD-U liquid medium, and culture it at 28℃, 200rpm overnight. Then inoculate it into 200mL YPGE liquid medium at a ratio of 1:50 and activate it at 28℃, 200rpm. When the OD600 is about 3, add galactose to a final concentration of 2%. Continue to culture at 28℃, 200rpm for 24h. Centrifuge the harvested bacterial solution at 8000rpm and remove the supernatant. Wash 3-5 times with 25mL washing buffer (the washed bacteria can be temporarily frozen in a -80℃ refrigerator); resuspend the bacteria with 3mL resuspension buffer and dispense the liquid into 1.5mL centrifuge tubes, with a maximum of 500μL of bacteria in each tube, and add quartz sand, the volume of which is about 1 / 3 of the bacteria; grind and break the yeast cell wall with a tissue grinder, and ensure that the bacteria are in a low temperature state during grinding to prevent the activity of the microsomes from being destroyed by excessive temperature; after the yeast cell wall is completely broken, centrifuge the sample at 12000rpm at 4℃ for 15min to remove yeast cell fragments, and transfer the supernatant after centrifugation to a special ultracentrifuge tube; centrifuge the sample supernatant at 100000g and 4℃ for 60min in an ultracentrifuge, and the precipitate after ultracentrifugation is the microsomal protein; discard the supernatant and transfer the microsomal protein to the storage buffer; resuspend the microsomal protein with an appropriate amount of storage buffer, and mix it with a pipette tip to obtain the microsomal protein containing HNDM.

[0038] (2) Verification of HNDM microsomal protease activity

[0039] The catalytic reaction buffer was 100 mM potassium phosphate buffer (pH 7.4), L-scopolamine was used as the reaction substrate at a final concentration of 0.5 mM, and the hydrogen ion donor was NADPH at a final concentration of 3 mM. The amount of protein added to each reaction system was 600 μg, the reaction temperature was 30°C, and the reaction time was 30 min.

[0040] When conducting the microsome catalytic activity identification test, the reaction sample addition system is shown in Table 1:

[0041]

[0042] After the reaction, 1 / 15 of the reaction volume of ammonia water was added to terminate the enzymatic reaction and adjust the pH of the reaction system, and then an equal volume of chloroform was added for extraction. After vortex mixing, the mixture was centrifuged at 12000 rpm for 10 min, and the lower layer of chloroform was aspirated. After repeated extraction three times, the extracted enzyme activity reaction sample was blown dry with nitrogen, and the reaction product was fully dissolved with 1 mL of chromatographic grade methanol. After centrifugation at 12000 rpm for 10 min, 600 μL of the upper layer liquid was aspirated into the injection bottle with a pipette, and the product generated after the catalytic reaction was analyzed by HPLC-MS. The high-resolution mass spectrometer was Orbitrap Exploris 120 (Thermo Scientific), the chromatographic column was Thermo's Hypersil GOLD C18 reverse phase silica gel column (1.9 μm, 100×2.1 mm), the mobile phase A was 0.1% formic acid aqueous solution, and B was acetonitrile. The gradient elution was adopted. The UPLC elution program is shown in Table 2:

[0043] Table 2. Elution procedure

[0044]

[0045] The column temperature was set at 35°C, the flow rate was 0.3 mL / min, the injection volume was 1 μL, the mass spectrometer used an electrospray ionization source (ESI), and the ion mode was positive. The test results showed that the mass-to-charge ratio of the product of the HNDM-catalyzed scopolamine demethylation reaction was 276.1588 (M+H + ), and the theoretical mass-to-charge ratio of scopolamine is 276.1594 (M+H + ) Figure 1 and Figure 2 The results of in vitro microsomal protein activity showed that HNDM had the activity of catalyzing the demethylation reaction of scopolamine to generate norscopolamine.

[0046] Example 3: Overexpression of HNDM increases the content of scopolamine in belladonna

[0047] (1) Construction of HNDM plant overexpression vector

[0048] In order to study whether the HNDM gene can increase the content of scopolamine in belladonna, the HNDM plant overexpression vector pBI121-HNDM was constructed, and the original plasmid was pBI121. First, the GUS gene on the original plasmid was replaced with the HNDM gene using the restriction sites BamH I and Sac I. The HNDM gene was amplified by PCR using belladonna cDNA as a template and the sequences shown below as primers to obtain the HNDM plant overexpression vector pBI121-HNDM. The primer sequences used are as follows:

[0049] BamHI-HNDM-F: 5′-TAGAGGATCCATGGATTTTCATATTCTTTCCCATG-3′ (SEQ ID

[0050] NO.7);

[0051] SacI-HNDM-R: 5′-TTCGAGCTCTTAAACCTCATAATACACAGGAATCAT-3′ (SEQ IDNO.8);

[0052] (2) Obtaining engineered Agrobacterium rhizogenes

[0053] The pBI121-HNDM vector was transferred into Agrobacterium rhizogenes (such as C58C1) by freeze-thaw method and PCR verification was performed. The results showed that the plant binary overexpression vector containing HNDM had been successfully transformed into the Agrobacterium rhizogenes strain.

[0054] (3) Obtaining transgenic roots

[0055] A. Co-cultivation of Agrobacterium and explants

[0056] Cut the leaves of sterile solanum seedlings into 1 cm 2 The size of the leaves was adjusted, and appropriate wounds were made on the leaves with scissors. The leaves were added with the activated resuspension of the engineering bacteria of Agrobacterium rhizogenes containing the HNDM plant binary overexpression vector (MS+AS 100 μmol / L). The bacterial solution was fully in contact with the explants for 5 minutes, and the leaves were transferred to the co-cultivation medium (MS+AS 100 μmol / L) and cultured at 25°C in the dark for 2 days.

[0057] B. Screening of resistant hairy roots

[0058] The solanum explants co-cultured for 2 days were transferred to a screening medium (MS+Kan 100mg / L+Cef400mg / L) and cultured in the dark at 25°C, subcultured once a week, and Kan-resistant hairy roots were obtained after 1-2 subcultures. The hairy roots with good growth were cut off and transferred to a culture medium (MS+Cef 200mg / L) and cultured until they were completely sterile, thereby obtaining Kan-resistant solanum hairy roots.

[0059] C. Genomic PCR and expression level detection of hairy roots

[0060] According to the 35S promoter region and HNDM upstream of the expression cassette where the target gene is located, forward primers and reverse primers were designed to detect the target gene. The results showed that the designed PCR specific primers could amplify specific DNA fragments. However, when the genomic DNA of non-transformed belladonna hairy roots was used as a template, no fragments were amplified. The transgenic belladonna hairy roots obtained were tested by fluorescent quantitative PCR, and the results were as follows: Figure 3 As shown, the expression level of HNDM gene in transgenic hairy roots was significantly increased.

[0061] D. Extraction and determination of scopolamine in hairy roots

[0062] The hairy roots were harvested after 30 days of shaking culture in MS culture medium, and the materials were freeze-dried to constant weight in a freeze dryer. After grinding into fine powder with a tissue grinder, 25 mg of the sample was accurately weighed in a 1.5 mL centrifuge tube using a 1 / 10,000 balance, and 1 mL of belladonna alkaloid extract (20% methanol + 0.1% formic acid) was added and mixed by inversion, and then placed in a horizontal shaker at room temperature for 3 hours of shaking extraction. After the sample was centrifuged at 12000 rpm for 10 minutes at room temperature, 50 μL of the supernatant was drawn into a sample bottle containing 950 μL of chromatography-grade methanol, and the content of scopolamine was detected using UPLC-MS after mixing. The results are the average of three replicates, the error bars represent the standard deviation, and the statistical analysis was tested by t-test.

[0063] The results are as follows Figure 4 As shown, in the present invention, overexpression of HNDM in belladonna significantly increases the content of scopolamine. In belladonna hairy roots overexpressing HNDM, the relative content of scopolamine is 1.53-2.33 times that of the relative content of scopolamine in ordinary hairy roots of the same period.

[0064] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A scopolamine N-demethylase having the activity of catalyzing the demethylation reaction of scopolamine to generate N-demethylscopolamine, characterized in that: The amino acid sequence of the scopolamine N-demethylase is shown in SEQ ID NO.

4.

2. A gene for scopolamine N-demethylase having the activity of catalyzing the demethylation reaction of scopolamine to generate N-demethylscopolamine, characterized in that: The nucleic acid sequence of the scopolamine N-demethylase gene is shown in SEQ ID NO.

3.

3. A recombinant vector containing a nucleic acid sequence encoding the scopolamine N-demethylase according to claim 1.

4. A transformant containing the nucleic acid sequence encoding the scopolamine N-demethylase according to claim 1.

5. Use of the scopolamine N-demethylase according to claim 1 or the gene of the scopolamine N-demethylase according to claim 2 in increasing the content of N-demethylscopolamine in Solanaceae plants.

6. The use according to claim 5, characterized in that: The Solanaceae plant is Solanum belladonna, Datura or Tripterygium wilfordii.

7. Use of a recombinant vector containing a gene encoding the scopolamine N-demethylase according to claim 1 in increasing the N-demethylscopolamine content in Solanaceae plants.

8. The use according to claim 7, characterized in that: The recombinant vector is obtained by replacing the GUS gene on pBI121 with the nucleic acid sequence encoding the scopolamine N-demethylase.

9. Use of the scopolamine N-demethylase according to claim 1 as a catalyst for catalyzing the demethylation reaction of scopolamine to generate N-demethylscopolamine.

10. The use according to claim 9, characterized in that: The catalysis occurs within the host cell, or chemically synthesized in vitro.